key: cord-0924089-sefcnjkh
authors: Aksoy, Hasan; Yıldırım, Umut Mert; Ergen, Pınar; Gürel, Mehmet Salih
title: COVID‐19 induced telogen effluvium
date: 2021-11-06
journal: Dermatol Ther
DOI: 10.1111/dth.15175
sha: 21c6909c1409553b0f4fbcd506e59087f9541016
doc_id: 924089
cord_uid: sefcnjkh

COVID‐19 is a febrile, infectious illness that has previously been associated with telogen effluvium (TE). However, to date, no study has been conducted to determine the incidence of TE in those who have had COVID‐19. To assess the frequency of TE in post‐COVID‐19 patients and the correlation between the development of TE and the severity of COVID‐19, to understand whether emotional stress or medications are responsible for the development of TE. Totally 204 patients with a history of SARS‐CoV‐2 infection in the last 3 months were included in the study. The diagnosis of TE was made by history of excessive hair shedding, hair pull test, diffuse or bitemporal thinning, and absence of anisotrichosis in trichoscopy. Patients who did not have any TE cause other than COVID‐19 and whose hair loss started after COVID‐19 were considered as “COVID‐19 associated TE (CATE).” We found TE in 75 (36.7%) cases and androgenetic alopecia (AGA) in 85 (41.7%) cases. CATE was present in 27.9% of cases and developed on average 53.76 (± 23.772) days after COVID‐19 real‐time reverse transcription polymerase chain reaction (RT‐PCR) positivity. The proportion of patients with CATE was numerically higher in hospitalized patients compared to outpatients (31.7% vs. 24.3%; p = 0.238); and significantly higher in women compared to men (42.3% vs. 6.2%; p < 0.001), in patients with hypertension compared to those without hypertension (40.4% vs. 23.1%; p = 0.014), and in patients who had respiratory symptoms compared to those who had not (31.7% vs. 14.0%; p = 0.021). The patients with and without CATE were similar in terms of stress level and usage of COVID‐19 medications. Patients with AGA had a higher rate of hospitalization (69.4% vs. 35.3%; p < 0.001) and a higher incidence of fever (69.4% vs. 54.6%; p = 0.033) during COVID‐19, compared to those without. TE developed in approximately one‐quarter of people who have had COVID‐19, and our study is the first to detect it. The time to onset of CATE, which was 7–8 weeks after the SARS‐CoV‐2 RT‐PCR positivity, was not much different from post‐infectious TE. Patients with severe COVID‐19 seem to be more prone to develop TE. The presence of AGA is associated with a more severe COVID‐19. During the pandemic, clinicians should consider a previous SARS‐CoV‐2 infection in patients presenting with hair loss.

Telogen effluvium (TE) is the most common cause of nonscarring alopecia. It is characterized by a diffuse hair shedding, which manifests 2-3 months after a triggering event. Several triggering factors such as febril diseases, physiological or emotional stress, medications, endocrine abnormalities, organ failure, or nutritional deficiencies may result in TE. Immediate anagen release, abrupt termination of the anagen phase and premature entry into the telogen phase, is the pathomechanism of TE caused by febrile states, infectious diseases, or drugs. 1 The novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has previously been linked to TE. In several reports, TE has developed 2-12 weeks after the SARS-CoV-2 infection. 2, 3 The incidence of TE in New York City has been shown to increase by more than 400%, approximately 3-4 months after the COVID-19 was declared a pandemic. 4 However, to date, no studies have been conducted on the incidence of TE in the patients who have recovered from the COVID-19. Besides, the relationship between the severity of COVID-19 and the development of TE is unknown.

In the present study, we aimed to assess the incidence of TE developed following COVID-19 and the correlation between the development of TE and the severity of infection. Our secondary objectives were to determine whether psychological stress during infection or COVID-19 treatments caused TE.

We designed a prospective study in Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital between February 2021 and April 2021. Ethics approval was obtained from local ethics committee (2021/0123, clinicaltrials.gov NCT04834102). Patients who admitted to dermatology or infectious diseases outpatient clinics with any complaints and had a history of SARS-CoV-2 infection confirmed by realtime reverse transcription polymerase chain reaction (RT-PCR) in the last 3 months were enrolled in the study. Informed consent was obtained from all subjects.

The diagnosis of TE was made by typical history of excessive hair shedding (e.g., reduction of the ponytail in diameter, clogging of the shower drain by hairs) and following physical findings: positive pull test, diffuse or bitemporal thinning, and absence of anisotrichosis in trichoscopy. Hair pull test was done by grasping about 40-60 hairs between the thumb and index finger and pulling gently-firmly from the scalp. Pulling out of more than 10% of hair (≥4-6 hairs) was considered positive. Anisotrichosis in trichoscopy (>10% miniaturized hair) was deemed compatible with androgenetic alopecia (AGA).

Demographics, comorbidities, therapeutic agents used for COVID-19, and any history of alopecia or iron deficiency prior to COVID-19 were noted; and as an indicator for the severity of COVID-19; hospitalization status and -if hospitalized-length of hospital stay, peak body temperature, peak level of C-reactive protein (CRP), COVID-19 symptoms and their duration were recorded for all participants. Patients' stress levels during infection were assessed using a scale of 1-10; where 1 refers to "low or no stress" and 10 indicates "very high stress."

If the diagnosis of TE was made, subjects were investigated to exclude other common causes of TE such as anemia, iron deficiency, or thyroid dysfunction. Patients who had no other potential cause for TE except COVID-19 or who had anemia but had a history of hair loss started subsequent to COVID-19 were considered "COVID-19 associated TE (CATE)."

Statistical Package for Social Sciences (SPSS) v17.0 was used to analyze data. χ 2 test was used for categorical variables, Mann-Whitney or independent samples t tests were used for quantitative variables. p value of <0.05 was considered significant. Table 1 ). The development of CATE was an average of 53.76 (± 23.772) days after COVID-19 RT-PCR positivity. COVID-19 associated TE was more frequent but not statistically significant in hospitalized patients compared to outpatients (31.7% vs. 24.3%; p = 0.238).

Diagnosis COVID-19 associated TE was more common in women than men.

Some authors attribute the higher incidence of TE in women to the fact that women take hair loss more seriously than men and that they are more prone to consult a physician with this complaint. 1 The medications used for COVID-19 may also play a role in the development of TE. In particular, the use of anticoagulants has been linked to the occurrence of TE previously. 10 However, in the present study, TE was not found more frequently in patients who have used any drug than in those who have not used it. It is known that emotional stress is another potential cause of TE. 1, 11 In previous publications on the relationship between the COVID-19 pandemic and TE, it has been speculated that the psychosocial stress resulting from the pandemic itself and/or "stay at home" orders may be responsible for the increased incidence of TE. 4, 12 However, we found the mean stress scores of patients with CATE during infection to be similar to those without CATE. These findings suggest that CATE is caused by the infection itself, not the drugs or emotional stress.

The higher incidence of fever and hospitalization rates in those with AGA in our study is consistent with literature data suggesting that AGA is associated with a more severe course of COVID-19. The relationship between AGA and severe COVID-19 may be due to androgen receptor hyperactivation, since androgen receptors involved in the pathogenesis of AGA regulate the transmembrane protease serine-2, which plays a role in the entry of SARS-CoV-2 into the cell. 13 Several pathogenetic mechanisms have been suggested previously to explain COVID-19 associated TE. Pro-inflammatory cytokines such as IL-6, TNFα, IL-1β, and IFNγ, which are released during systemic hyperinflammation of the COVID-19 may be responsible for the inhibition of hair shaft elongation, damage to matrix cells, and catagen development. [14] [15] [16] Microthrombotic reaction due to decreased concentration of anticoagulant proteins, occlusion of the hair follicle vasculature, and the resulting cell death is another hypothesis. 6 

Telogen effluvium: a review of the literature

Telogen effluvium: a sequela of COVID-19

Telogen effluvium related to post severe Sars-Cov-2 infection: clinical aspects and our management experience

A surge in the incidence of Telogen effluvium in minority predominant communities heavily impacted by COVID-19

Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic

Trichodynia and telogen effluvium in COVID-19 patients -results of an international expert opinion survey on diagnosis and management

SARS-CoV-2-induced telogen effluvium: a multicentric study

Telogen effluvium

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression

Traditional anticoagulants and hair loss: a role for direct Oral anticoagulants? A review of the literature

Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia

Management of telogen effluvium during the COVID-19 emergency: psychological implications

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the "Gabrin sign

Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients

Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles

Time of onset and duration of post-COVID-19 acute telogen effluvium

Telogen effluvium associated with COVID-19 infection

The authors have no conflicts of interest to declare. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-5207-9633